LONDON (Reuters) - AstraZeneca has signed a clinical study collaboration with U.S. biotech company Incyte, highlighting its desire to push ahead with drug development despite an unwanted $106 billion bid approach from Pfizer.
The agreement will test a combination of two different drugs designed to boost the immune system to help it fight tumours - AstraZeneca's MEDI4736 and Incyte's INCB24360 - in a Phase I/II clinical study, the British firm said on Wednesday.
(Reporting by Ben Hirschler; editing by Jason Neely)